[Asia Economy Reporter Minji Lee] On the 13th, Naibec announced that it has applied to the Australian Human Research Ethics Committee for a Phase 1 clinical trial plan of its peptide-based pulmonary fibrosis treatment.
The company stated, "After completing Phase 1 in Australia, depending on the evaluation results of pharmacokinetic characteristics, safety, tolerability, and immunogenicity identified during this clinical process, we plan to proceed to the next phase of patient-targeted clinical trials." It added, "Based on the Phase 1 results, we intend to pursue joint commercialization development and technology transfer with global pharmaceutical companies and biotech firms."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
